DDInter1509 DDInter542
Pravastatin is the 6-alpha-hydroxy acid form of [mevastatin]. Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug. This drug was developed by Sankyo Co. Ltd.; however, the first approved pravastatin product was developed by Bristol Myers Squibb and FDA approved in 1991. Pravastatin is made through a fermentation process in which [mevastatin] is first obtained. The manufacturing process is followed by the hydrolysis of the lactone group and the biological hydroxylation with _Streptomyces carbophilus_ to introduce the allylic 6-alcohol group.
Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K. In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases.
Pravastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Dicoumarol
Pravastatin {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Dicoumarol
Pravastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Phenprocoumon
Phenprocoumon {u} (Compound) resembles {v} (Compound) Dicoumarol
Pravastatin {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Phenprocoumon
Phenprocoumon {u} (Compound) resembles {v} (Compound) Dicoumarol
Pravastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Warfarin {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Dicoumarol
Pravastatin {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Acenocoumarol
Acenocoumarol {u} (Compound) resembles {v} (Compound) Dicoumarol
Pravastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Dicoumarol
Pravastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Dicoumarol
Pravastatin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Simvastatin
Simvastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Dicoumarol
Pravastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} (Compound) downregulates {v} (Gene) VKORC1
VKORC1 {u} (Gene) is bound by {v} (Compound) Dicoumarol
Pravastatin may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin (Compound) resembles Dicoumarol (Compound)
Pravastatin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dicoumarol (Compound)
Pravastatin may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin (Compound) resembles Phenprocoumon (Compound) and Phenprocoumon (Compound) resembles Dicoumarol (Compound)
Pravastatin (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Phenprocoumon (Compound) and Phenprocoumon (Compound) resembles Dicoumarol (Compound)
Pravastatin may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dicoumarol (Compound)
Pravastatin (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Acenocoumarol (Compound) and Acenocoumarol (Compound) resembles Dicoumarol (Compound)
Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin (Compound) resembles Dicoumarol (Compound)
Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dicoumarol (Compound)
Pravastatin (Compound) resembles Simvastatin (Compound) and Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin (Compound) resembles Dicoumarol (Compound)
Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib (Compound) downregulates VKORC1 (Gene) and VKORC1 (Gene) is bound by Dicoumarol (Compound)